

The Medical Letter[®]

on Drugs and Therapeutics

Volume 64

January 10, 2022

ISSUE No.
1641

IN THIS ISSUE

In Brief: Twice-Yearly Paliperidone (*Invega Hafyera*) for Schizophrenia..... p 7

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying or any distribution of this material is prohibited.

Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 64 (Issue 1641)

January 10, 2022

Take CME Exams

IN BRIEF

Twice-Yearly Paliperidone (*Invega Hafyera*) for Schizophrenia

Invega Hafyera (Janssen), a long-acting, extended-release (ER) formulation of the second-generation antipsychotic paliperidone palmitate, has been approved by the FDA for twice-yearly IM treatment of schizophrenia in adults who have been adequately treated with another injectable ER formulation of the drug (*Invega Sustenna* or *Invega Trinza*). It is the first drug to become available in the US for twice-yearly treatment of schizophrenia.

Pronunciation Key

Invega Hafyera: in vay' guh haf' ye ra"

LONG-ACTING INJECTABLE ANTIPSYCHOTICS – Long-acting injectable antipsychotics are generally used in patients with a history of relapse due to poor adherence to oral maintenance therapy. They are

believed to improve adherence, hospitalization and relapse rates, and long-term outcomes in patients with schizophrenia, even though a benefit has not been consistently demonstrated in controlled trials comparing long-acting injectable formulations with oral second-generation antipsychotics.^{1,2}

CLINICAL STUDIES – FDA approval of *Invega Hafyera* was based on the results of an unpublished (summarized in the package insert) double-blind, active-controlled, noninferiority trial in 702 adults with schizophrenia. At 12 months, a relapse event occurred in 7.5% of patients who received *Invega Hafyera* every 6 months and in 4.9% of those who received the drug every 3 months (*Invega Trinza*); twice-yearly paliperidone was noninferior to the drug given every 3 months.

ADVERSE EFFECTS – Adverse effects of the new twice-yearly paliperidone palmitate formulation appear to be similar to those with the other injectable ER formulations of the drug.

Table 1. Long-Acting Injectable Second-Generation Antipsychotics

Drug	Formulations	Usual Adult Dosage ^{1,2}	Cost ³
Aripiprazole – <i>Abilify Maintena</i> (Otsuka/Lundbeck)	300, 400 mg prefilled syringes, vials	400 mg IM once/month	\$2388.50
Aripiprazole lauroxil – <i>Aristada</i> (Alkermes)	441, 662, 882, 1064 mg prefilled syringes	441, 662, or 882 mg IM once/month or 882 mg IM q6 weeks or 1064 mg q2 months ⁴	1413.60
Olanzapine pamoate – <i>Zyprexa Relprevv</i> (Lilly)	210, 300, 405 mg vials	150 or 300 mg IM q2 weeks or 300 or 405 mg IM once/month	842.40
Paliperidone palmitate – <i>Invega Sustenna</i> (Janssen)	39, 78, 117, 156, 234 mg prefilled syringes	117, 156, or 234 mg IM once/month	1470.00
<i>Invega Trinza</i>	273, 410, 546, 819 mg prefilled syringes	410, 546, or 819 mg IM q3 months	4410.00
<i>Invega Hafyera</i>	1092, 1560 mg prefilled syringes	1092 or 1560 mg IM q6 months ⁵	11,760.30
Risperidone – <i>Risperdal Consta</i> (Janssen)	12.5, 25, 37.5, 50 mg vials	25, 37.5, or 50 mg IM q2 weeks	1065.80
<i>Perseris</i> (Indivior)	90, 120 mg kits	90 or 120 mg SC once/month	1185.30

1. Dosage adjustments may be needed for renal or hepatic impairment.

2. Initial dosage of long-acting formulations for schizophrenia is based on patient's stable oral maintenance dosage. Dosage of *Invega Trinza* is based on the previous dose of *Invega Sustenna*; dosage of *Invega Hafyera* is based on the previous dose of *Invega Sustenna* or *Invega Trinza*.

3. Approximate WAC for 4 weeks' or 1 month's treatment with the lowest usual adult dosage (3 months' treatment with *Invega Trinza*, 6 months' treatment with *Invega Hafyera*). WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. December 5, 2021. Reprinted with permission by First Databank, Inc. All rights reserved. ©2021. www.fdbhealth.com/policies/drug-pricing-policy.

4. A single 675-mg IM dose of *Aristada Initio* and one 30-mg dose of oral aripiprazole or 21 days of oral aripiprazole should be given in conjunction with the first dose of *Aristada*.

5. The starting dose is 1092 mg if switching from *Invega Sustenna* 156 mg once/month or *Invega Trinza* 546 mg q3 months. The starting dose is 1560 mg if switching from *Invega Sustenna* 234 mg once/month or *Invega Trinza* 819 mg q3 months.

DRUG INTERACTIONS – Concurrent use of strong CYP3A4 and P-glycoprotein (P-gp) inducers can decrease serum concentrations of paliperidone and should be avoided; if coadministration is necessary, oral paliperidone extended-release tablets can be added.³ Paliperidone may antagonize the effects of levodopa and other dopamine agonists.

DOSAGE AND ADMINISTRATION – *Invega Hafyera* is injected into the gluteal muscle once every 6 months. The starting dosage (1092 or 1560 mg) is based on the previous dose of the monthly or 3-month injectable ER formulations of paliperidone palmitate and should be administered at the time

the next dose of paliperidone palmitate is scheduled. Dosage adjustments can be made every 6 months between 1092 mg and 1560 mg. *Invega Hafyera* is not recommended for use in patients with any degree of renal impairment (CrCl <90 mL/min). ■

1. Drugs for psychotic disorders. *Med Lett Drugs Ther* 2016; 58:160.
2. GA Keepers et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. *Am J Psychiatry* 2020; 177:868.
3. Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. *Med Lett Drugs Ther* 2021 October 20 (epub). Available at: http://secure.medicalletter.org/downloads/CYP_PGP_Tables.pdf.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT AND EXECUTIVE EDITOR:** Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School
VICE PRESIDENT AND EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhM, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The editors do not warrant that all the material in this publication is accurate and complete in every respect. The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
 145 Huguenot St. Ste. 312
 New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
 Fax: 914-632-1733
 E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue, please e-mail your request to: permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
 3 years - \$398. \$65 per year
 for students, interns, residents,
 and fellows in the US and Canada.
 Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
 Call: 800-211-2769
 Special rates available for bulk
 subscriptions.

Get Connected:  

Copyright 2022. ISSN 1523-2859

